Gayed Isis W, Kim E Edmund, Broussard William F, Evans Douglass, Lee Jeffrey, Broemeling Lyle D, Ochoa Breanna B, Moxley Donna M, Erwin William D, Podoloff Donald A
Department of Nuclear Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
J Nucl Med. 2005 Feb;46(2):248-52.
As SPECT/CT technology evolves, its applications and indications need to be evaluated clinically for more efficient and cost-effective use. This retrospective study evaluated the clinical value of simultaneously acquired (99m)Tc-sestamibi SPECT/CT versus conventional SPECT in diagnosing and locating parathyroid adenomas or hyperplasia in patients with primary hyperparathyroidism.
Immediately and 60 minutes after intravenous administration of 740-925 MBq of (99m)Tc-sestamibi, static planar images of the neck and chest were obtained. SPECT/CT images were acquired 30 minutes after injection. Two experienced masked readers independently evaluated whether conventional SPECT images provided information beyond what was available from the planar images either by changing the diagnosis or by better locating the glands and whether the SPECT/CT images provided information beyond what was available from the planar plus conventional SPECT images. Forty-eight consecutive patients with a clinical diagnosis of primary hyperparathyroidism were included in the study. The 32 whose scans showed positive results underwent surgical resection and were examined histopathologically.
Planar and SPECT imaging, with or without CT fusion, identified 89% of the surgically confirmed diseased parathyroid glands. Use of SPECT/CT changed the diagnosis in only 1 patient (2%) from positive to negative and better located the glands in only 4 patients (8%). SPECT/CT was particularly helpful in locating the 2 ectopic parathyroid adenomas diagnosed in this cohort. Tracer retention in diseased glands did not correlate with histologic characteristics. Also, biochemical markers did not correlate with the scan findings.
SPECT/CT has no significant clinical value additional to that of conventional SPECT for parathyroid imaging except in locating ectopic parathyroid glands. Eliminating the CT acquisition will spare patients the additional time, radiation exposure, and expense.
随着单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)技术的发展,需要对其临床应用和适应症进行评估,以实现更高效且具成本效益的使用。这项回顾性研究评估了同步采集的(99m)锝-司他米比SPECT/CT与传统SPECT在诊断和定位原发性甲状旁腺功能亢进患者的甲状旁腺腺瘤或增生方面的临床价值。
静脉注射740 - 925MBq的(99m)锝-司他米比后即刻及60分钟后,获取颈部和胸部的静态平面图像。注射后30分钟采集SPECT/CT图像。两名经验丰富的盲法阅片者独立评估传统SPECT图像是否通过改变诊断或更好地定位腺体提供了超出平面图像的信息,以及SPECT/CT图像是否提供了超出平面图像加传统SPECT图像的信息。连续48例临床诊断为原发性甲状旁腺功能亢进的患者纳入研究。扫描结果呈阳性的32例患者接受手术切除并进行组织病理学检查。
平面成像和SPECT成像(无论有无CT融合)识别出了89%经手术证实的患病甲状旁腺。SPECT/CT仅使1例患者(2%)的诊断从阳性变为阴性,仅使4例患者(8%)的腺体定位更佳。SPECT/CT在定位该队列中诊断出的2例异位甲状旁腺腺瘤方面特别有帮助。病变腺体中的示踪剂滞留与组织学特征无关。此外,生化标志物与扫描结果也无关。
除了定位异位甲状旁腺外,SPECT/CT在甲状旁腺成像方面相较于传统SPECT没有显著的额外临床价值。省去CT采集将使患者节省额外的时间、辐射暴露和费用。